325 related articles for article (PubMed ID: 26321211)
1. Lack of access to targeted cancer therapy.
Burki TK
Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321211
[No Abstract] [Full Text] [Related]
2. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.
Farwell MD; Clark AS; Mankoff DA
JAMA Oncol; 2015 Jul; 1(4):421-2. PubMed ID: 26181243
[No Abstract] [Full Text] [Related]
3. The Future of Precision Oncology for the Treatment of Solid Tumors.
Klute KA
Clin Pharmacol Ther; 2020 Sep; 108(3):416-418. PubMed ID: 31983061
[No Abstract] [Full Text] [Related]
4. Personalising the treatment of prostate cancer.
Gunjur A
Lancet Oncol; 2015 Dec; 16(16):e592. PubMed ID: 26549591
[No Abstract] [Full Text] [Related]
5. Anticipating designer drug-resistant cancer cells.
Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
[TBL] [Abstract][Full Text] [Related]
6. Giving Up on Precision Oncology? Not So Fast!
Warner JL
Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
[No Abstract] [Full Text] [Related]
7. Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques--the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies.
Nicoś M; Wojas-Krawczyk K; Krawczyk P; Milanowski J
Adv Clin Exp Med; 2015; 24(4):715-23. PubMed ID: 26469118
[TBL] [Abstract][Full Text] [Related]
8. Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics.
Comment LA; Ward AF; Schrock AB; Fabrizio D; Venstrom JM; Hegde PS; Alexander BM
Clin Pharmacol Ther; 2020 Sep; 108(3):440-443. PubMed ID: 32744335
[No Abstract] [Full Text] [Related]
9. Drug sensitivity testing platforms for gastric cancer diagnostics.
Lau V; Wong AL; Ng C; Mok Y; Lakshmanan M; Yan B
J Clin Pathol; 2016 Feb; 69(2):93-6. PubMed ID: 26567318
[TBL] [Abstract][Full Text] [Related]
10. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
Blumenthal GM; Mansfield E; Pazdur R
JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
[No Abstract] [Full Text] [Related]
11. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
Horlings HM; Shah SP; Huntsman DG
JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
[No Abstract] [Full Text] [Related]
12. Molecular pathology in therapeutics: where are we now, and where are we going?
Harrison DJ; Faratian D
Curr Drug Targets; 2012 Nov; 13(12):1473-4. PubMed ID: 22974390
[No Abstract] [Full Text] [Related]
13. Delivering on the promise of precision cancer medicine.
Berger MF; Van Allen EM
Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
[No Abstract] [Full Text] [Related]
14. A precision, personalized approach to the management of bladder cancer.
Apolo AB; Burger M
Curr Opin Urol; 2015 Sep; 25(5):416-7. PubMed ID: 26153639
[No Abstract] [Full Text] [Related]
15. Precision medicine: lessons learned from the SHIVA trial.
Weiss GJ
Lancet Oncol; 2015 Dec; 16(16):e580. PubMed ID: 26678199
[No Abstract] [Full Text] [Related]
16. Precision medicine: lessons learned from the SHIVA trial.
Hahn AW; Martin MG
Lancet Oncol; 2015 Dec; 16(16):e580-1. PubMed ID: 26678198
[No Abstract] [Full Text] [Related]
17. Precision medicine: lessons learned from the SHIVA trial.
Tsimberidou AM; Kurzrock R
Lancet Oncol; 2015 Dec; 16(16):e579-80. PubMed ID: 26678197
[No Abstract] [Full Text] [Related]
18. The evolving potential of companion diagnostics.
Khoury JD
Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
[TBL] [Abstract][Full Text] [Related]
19. Precision cancer medicine: the future is now, only better.
Tsimberidou AM; Eggermont AM; Schilsky RL
Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine: lessons learned from the SHIVA trial - Authors' reply.
Le Tourneau C; Belin L; Paoletti X; Bièche I; Kamal M
Lancet Oncol; 2015 Dec; 16(16):e581-2. PubMed ID: 26678200
[No Abstract] [Full Text] [Related]
[Next] [New Search]
